Evaluate Aerobic Exercise on Myocardial Fibrosis and Intestinal Flora in Dilated Cardiomyopathy Diagnosed First Time.

Sponsor
Nanjing Medical University (Other)
Overall Status
Recruiting
CT.gov ID
NCT06039969
Collaborator
(none)
30
1
24
1.2

Study Details

Study Description

Brief Summary

To invegstive the Changes of Intestinal Flora and the improvements of Cardiac Fibrosis in Patients With Dilated Cardiomyopathy Diagnosed for the First Time by heart Rehabilitation

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Previous studies have confirmed that Aerobic exercise rehabilitation can reduce the rate of readmission of patients with heart failure and improve their cardiopulmonary endurance and exercise ability. However, whether aerobic exercise rehabilitation can inhibit myocardial fibrosis or delay the progress of fibrosis in patients with heart failure has not been reported. At the same time, some studies have shown that the change of intestinal microbial flora may promote the progress of heart failure, and regular aerobic exercise will also lead to the change of intestinal microbial flora, but whether aerobic exercise rehabilitation can improve intestinal microbial flora in patients with dilated cardiomyopathy has not been reported. In our study, patients who were hospitalized for heart failure for the first time and were finally diagnosed with dilated cardiomyopathy were recruited. Recruited patients will enter the routine cardiac rehabilitation process and make an individualized aerobic exercise plan according to the cardiopulmonary exercise test. Cardiac MRI and intestinal microflora changes will be evaluated.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    30 participants
    Observational Model:
    Case-Crossover
    Time Perspective:
    Prospective
    Official Title:
    Study on the Changes of Intestinal Flora and Cardiac Fibrosis in Patients With Dilated Cardiomyopathy Diagnosed for the First Time by Sports Rehabilitation
    Anticipated Study Start Date :
    Oct 1, 2023
    Anticipated Primary Completion Date :
    Oct 1, 2024
    Anticipated Study Completion Date :
    Oct 1, 2025

    Arms and Interventions

    Arm Intervention/Treatment
    Cardiac MRI will be performed in patients with heart failure caused by cardiomyopathy.

    Cardiac MRI will be performed in patients with heart failure caused by cardiomyopathy. At the same time Collect patient feces.this is a obvertional study ,ther is no intervetion

    Outcome Measures

    Primary Outcome Measures

    1. myocardial fibrosis [first admission six months one year]

      Assessment of myocardial fibrosis based on cardiac MRI examination

    Secondary Outcome Measures

    1. Bacterial spectrum of intestine [first admission six months one year]

      Assessment of Bacterial spectrum of intestine based on Patient feces sequencing

    Other Outcome Measures

    1. cardiac fitiness [first admission six months one year]

      Assessment of caridac fitness based on ardiopulmonary exercise test

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • 1、Patients hospitalized for the first time because of heart failure 2、The patient who was definitely diagnosed as dilated cardiomyopathy for the first time
    Exclusion Criteria:
    • 1、Other types of cardiomyopathy 2、Has been diagnosed as dilated cardiomyopathy. 3、malignant tumor 4、acute infection 5、Cannot perform cardiopulmonary exercise test.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Huai'An First People'S Hospital Huai'an Jiangsu China 223300

    Sponsors and Collaborators

    • Nanjing Medical University

    Investigators

    • Study Director: XiWen Zhang, MD, Huai'an First People's Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Jin Geng, associate doctor, Nanjing Medical University
    ClinicalTrials.gov Identifier:
    NCT06039969
    Other Study ID Numbers:
    • 20230911
    First Posted:
    Sep 15, 2023
    Last Update Posted:
    Sep 15, 2023
    Last Verified:
    Sep 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Keywords provided by Jin Geng, associate doctor, Nanjing Medical University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 15, 2023